Company Description
Retractable Technologies, Inc. designs, develops, manufactures, and markets safety syringes and other safety medical products for the healthcare profession in the United States, rest of North and South America, and internationally.
It offers VanishPoint insulin syringes; tuberculin, insulin, and allergy antigen syringes; small diameter tube adapters; blood collection tube holders; allergy trays; IV safety catheters; Patient Safe syringes and Luer Caps; VanishPoint blood collection sets; EasyPoint needles; and VanishPoint autodisable syringes.
The company distributes its products through general line and specialty distributors, as well as through international distributors; and a direct marketing network.
Retractable Technologies, Inc. was incorporated in 1994 and is headquartered in Little Elm, Texas.
| Country | United States |
| IPO Date | May 4, 2001 |
| Industry | Medical - Instruments & Supplies |
| Sector | Healthcare |
| Employees | 148 |
| CEO | Thomas J. Shaw |
Contact Details
Address: 511 Lobo Lane Little Elm, Texas United States | |
| Website | https://www.retractable.com |
Stock Details
| Ticker Symbol | RVP |
| Exchange | AMEX |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000946563 |
| CUSIP Number | 76129W105 |
| ISIN Number | US76129W1053 |
| Employer ID | 75-2599762 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Thomas J. Shaw | Founder, Chairman, President & Chief Executive Officer |
| John W. Fort III | Vice President, Chief Financial Officer, Principal Accounting Officer,Treasurer & Director |
| Lawrence G. Salerno | Director of Operations |
| Michele M. Larios Esq. | Vice President, General Counsel & Secretary |
| Russell B. Kuhlman | Vice President of Sales Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 11, 2024 | 4 | Filing |
| Dec 10, 2024 | 4 | Filing |
| Dec 09, 2024 | 4 | Filing |
| Dec 02, 2024 | 4 | Filing |
| Nov 14, 2024 | 8-K | Current Report |
| Nov 14, 2024 | 10-Q | Quarterly Report |
| Nov 14, 2024 | 4 | Filing |
| Nov 13, 2024 | 4 | Filing |
| Nov 12, 2024 | 4 | Filing |
| Nov 04, 2024 | 4 | Filing |